Can a digital swab test tell COVID and flu apart at home?
NCT ID NCT07743970
First seen Aug 04, 2026 · Last updated Sep 18, 2026 · Updated 4 times
Summary
This study evaluates a new digital test that people can use at home to detect COVID-19 and influenza A and B from a nasal swab. Participants with symptoms will use the test themselves and compare the results to a standard lab PCR test. The goal is to see if the test is accurate enough for over-the-counter use, potentially offering a convenient way to identify these infections without visiting a clinic.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NowFuture Digital Flu / COVID Test (a digital diagnostic test for SARS-CoV-2, influenza A, and influenza B antigens from nasal swabs)
- What this could lead to
- If accurate, this could enable convenient, over-the-counter home testing for COVID-19 and flu, helping people get quick results without a lab visit.
- What could go wrong
- The test is still being validated, and its accuracy may not match lab tests. User error or sample issues could affect results, and the study is limited to people with symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2026
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
2 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Written informed consent obtained prior to study enrollment. * Male or female aged 2 years of age and older. * Participant is currently exhibiting at least one symptom (i.e. symptomatic) associated with COVID-19 or influenza (such as, but not limited to, fever, headache, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea) and must present within 6 days of symptom onset (equates to 5 DPSO). Subject must still be exhibiting symptom(s) on the day of sample collection. Exclusion Criteria: * Participant or participant's legally acceptable representative (for minors) who is 18 years of age (or the state's legal age of majority) or older and does not understand or is not able and willing to sign the study informed consent. * Participant who has had a positive SARS-CoV-2, Influenza A and/or Influenza B result within the past 30 days. * Participant has had seasonal influenza vaccine such as the FluMist/FluMist Quadrivalent live intranasal influenza vaccine and/or the SARS-CoV-2 vaccine within the past 5 days. * Participant is not able to tolerate sample collection or is not willing to contribute the required swab samples for testing or complete the study procedures. * Participant is currently undergoing antiviral treatment such as baloxavir marboxil (Xofluza), oseltamivir (Tamiflu®), zanamivir (Relenza®), and peramivir (Rapivab®). * Participant currently undergoing treatment and/or has undergone treatment within the past thirty (30) days with prescription medication to treat Coronavirus SARS-CoV-2 infection, which may include but is not limited to Remdesivir (Veklury), Paxlovid, molnupiravir or receiving convalescent plasma therapy for SARS-CoV-2. * Participant who has had a nasal wash or aspirate as part of their standard of care treatment on day of study visit prior to the study sample collection. * Participant who has had recent craniofacial injury or surgery, including to correct deviation of the nasal septum, within the previous six (6) months.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Influenza A virus infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Brecken Health
RECRUITINGBunbury, Western Australia, 6230, Australia
-
Clinical Trials Institute Torquay
RECRUITINGTorquay, Victoria, 3228, Australia
-
Paratus Western Sydney
RECRUITINGBlacktown, New South Wales, 2148, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill stop COVID-19 before it starts?
- Why COVID-19 hits blood cancer patients harder: scientists map the immune clues
- The household maze: how does COVID-19 move between family members?
- New mRNA booster shot put to the test against comirnaty
- Can a second janssen shot cut severe COVID-19 in south africa?
- Can new vaccines outsmart COVID-19 variants?